- Home
- PHUN vs KPTI Comparison
PHUN vs KPTI Comparison
Compare PHUN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- KPTI
- Stock Information
- Founded
- PHUN 2009
- KPTI 2008
- Country
- PHUN United States
- KPTI United States
- Employees
- PHUN N/A
- KPTI N/A
- Industry
- PHUN EDP Services
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- KPTI Health Care
- Exchange
- PHUN Nasdaq
- KPTI Nasdaq
- Market Cap
- PHUN 64.1M
- KPTI 44.5M
- IPO Year
- PHUN N/A
- KPTI 2013
- Fundamental
- Price
- PHUN $3.42
- KPTI $4.61
- Analyst Decision
- PHUN Buy
- KPTI Buy
- Analyst Count
- PHUN 2
- KPTI 6
- Target Price
- PHUN $7.75
- KPTI $48.50
- AVG Volume (30 Days)
- PHUN 338.2K
- KPTI 55.2K
- Earning Date
- PHUN 08-07-2025
- KPTI 08-05-2025
- Dividend Yield
- PHUN N/A
- KPTI N/A
- EPS Growth
- PHUN N/A
- KPTI N/A
- EPS
- PHUN N/A
- KPTI N/A
- Revenue
- PHUN $2,956,000.00
- KPTI $142,126,000.00
- Revenue This Year
- PHUN $3.01
- KPTI $2.09
- Revenue Next Year
- PHUN $50.72
- KPTI $12.90
- P/E Ratio
- PHUN N/A
- KPTI N/A
- Revenue Growth
- PHUN N/A
- KPTI 1.19
- 52 Week Low
- PHUN $2.22
- KPTI $3.51
- 52 Week High
- PHUN $14.60
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- PHUN 59.76
- KPTI 51.08
- Support Level
- PHUN $2.95
- KPTI $4.12
- Resistance Level
- PHUN $3.10
- KPTI $4.64
- Average True Range (ATR)
- PHUN 0.17
- KPTI 0.30
- MACD
- PHUN 0.02
- KPTI 0.05
- Stochastic Oscillator
- PHUN 84.58
- KPTI 67.12
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.